SPP1 and metabolic dysfunction-associated steatotic liver disease: Therefore, we selected AKR1B10 and SPP1 co-sensitive drugs TGX-221 as a possible therapy to inhibit or delay the progression of NAFLD and improve the prognosis of NAFLD-HCC.